PERP-B.ST BrightBid Group AB (publ)
- Market cap
- SEK 14.1M
- P/E
- 5.3x
- P/B
- 0.84x
- ROE
- -52.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PERP-B.ST undervalued?
Graham numberPERP-B.ST trades 55.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BrightBid Group AB (publ) fundamental analysis
No fundamental analysis for BrightBid Group AB (publ) yet.
BrightBid Group AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BrightBid Group AB (publ)
Perpetua Medical AB (publ) provides products and solutions for use of injectable drugs in Sweden. It provides DrugLog, a solution for reducing medication errors in pharmacy; WasteLog, a device that analysis waste and returns of injectable controlled substances; and PrepLog, a DrugLog based technology platform that integrated prescription software or medication management system for the test of drug preparations. The company formerly known as Pharmacolog i Uppsala AB (publ) a…
Full company profileBrightBid Group AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BrightBid Group AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 14.0K | 798K | 1.04M | 2.18M | 1.90M | 8.82M | 10.1M | 9.94M | 6.94M | 14.6M | 21.9M |
| Gross Profit | 14.0K | 1.05M | 806K | 1.54M | 944K | 5.93M | 6.65M | 5.85M | 3.14M | 7.60M | 10.3M |
| Operating Income | -11.1M | -9.65M | -12.3M | -15.5M | -14.5M | -13.7M | -19.1M | -18.5M | -2.46M | 2.04M | -11.9M |
| EBITDA | -9.84M | -8.30M | -11.8M | -16.1M | -13.9M | -13.2M | -18.6M | -18.3M | -1.80M | 4.40M | -6.59M |
| Net Income | -11.2M | -9.94M | -12.4M | -16.7M | -14.6M | -13.7M | -19.2M | -18.3M | -2.47M | 2.45M | -8.48M |
| EPS | -5.58 | -3.47 | -1.79 | -1.55 | -1.03 | -0.71 | -1.10 | -1.11 | -0.55 | 0.53 | -0.99 |
| Balance Sheet | |||||||||||
| Total Assets | 6.13M | 15.4M | 17.9M | 20.3M | 19.0M | 25.6M | 18.8M | 12.3M | 18.7M | 62.2M | 58.1M |
| Total Liabilities | 4.81M | 4.12M | 4.14M | 3.23M | 3.99M | 4.76M | 4.82M | 4.24M | 7.88M | 31.4M | 32.7M |
| Shareholders' Equity | 1.32M | 11.2M | 13.7M | 17.0M | 15.0M | 20.8M | 14.0M | 8.07M | 7.85M | 19.8M | 16.1M |
| Cash & Short-term Investments | 1.07M | 10.7M | 13.6M | 16.6M | 16.4M | 19.1M | 10.7M | 5.53M | 9.40M | 4.33M | 16.8M |
| Total Debt | 2.43M | 2.23M | 1.76M | 1.39M | 1.06M | 749K | 389K | 56.0K | 4.00M | 178K | 178K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -9.16M | -9.34M | -11.0M | -13.9M | -10.2M | -15.3M | -19.2M | -16.4M | -7.03M | -5.46M | -7.80M |
| Capital Expenditure | 700K | 662K | 406K | 230K | 204K | 795K | 1.05M | 620K | 33.4K | 1.07M | 5.50M |
| Free Cash Flow | -9.86M | -10.0M | -11.4M | -14.1M | -10.4M | -16.1M | -20.2M | -17.0M | -7.06M | -6.53M | -13.3M |
| Ratios | |||||||||||
| ROE | -852.7% | -88.5% | -90.2% | -98.2% | -97.5% | -65.8% | -136.6% | -226.5% | -31.5% | 12.4% | -52.8% |
| ROA | -183.4% | -64.7% | -69.3% | -82.6% | -76.9% | -53.6% | -101.7% | -148.5% | -13.2% | 3.9% | -14.6% |
| Net Profit Margin | -80,459.7% | -1,245.6% | -1,196.6% | -766.7% | -767.4% | -155.5% | -189.5% | -183.9% | -35.6% | 16.8% | -38.8% |
| Debt to Equity | 1.85x | 0.20x | 0.13x | 0.08x | 0.07x | 0.04x | 0.03x | 0.01x | 0.51x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BrightBid Group AB (publ) dividends
BrightBid Group AB (publ) has not paid dividends in the last 9 fiscal years.
Last stock split: 1:24 on Sep 26, 2024.
Who owns BrightBid Group AB (publ)
- Insiders 46.29%
- Institutions 29.25%
- Public & others 24.46%
- Shares outstanding 8.56M
- Free float 6.60M
BrightBid Group AB (publ) company profile
- Company name
- BrightBid Group AB (publ)
- Ticker
- PERP-B.ST
- ISIN
- SE0022726311
- Exchange
- Stockholm Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 12
- Fiscal year end
- December
- Address
- Knivstagatan 8, Uppsala, Sweden, SE-753 23
- Phone
- 46 1 87 11 332
- Website
- perpetuamedical.se
About BrightBid Group AB (publ)
Perpetua Medical AB (publ) provides products and solutions for use of injectable drugs in Sweden. It provides DrugLog, a solution for reducing medication errors in pharmacy; WasteLog, a device that analysis waste and returns of injectable controlled substances; and PrepLog, a DrugLog based technology platform that integrated prescription software or medication management system for the test of drug preparations. The company formerly known as Pharmacolog i Uppsala AB (publ) and changed its name to Perpetua Medical AB (publ) in April 2024. Perpetua Medical AB (publ) was incorporated in 2007 and is headquartered in Uppsala, Sweden. Perpetua Medical AB (publ) operates as a subsidiary of Nolsterby Invest AB.
BrightBid Group AB (publ) management
3- Mr. Anders HedlundCo-Founder & CEO · born 1985
- Mr. Hans DahlinFounder & Advisor to CEO
- Ms. Camilla LonnChief Financial Officer · born 1972